Skip to main content

Advertisement

SpringerLink
Log in

Targeted therapies

Time to shift the burden of proof for oncogene-positive cancer?

  • News & Views
  • Published:

From Nature Reviews Clinical Oncology

View current issue Sign up to alerts

Rearrangements of the ALK gene have been associated with sensitivity to crizotinib and other kinase inhibitors with activity against ALK. The phase III PROFILE 1007 randomized study of crizotinib versus chemotherapy has demonstrated that crizotinib is superior to standard second-line chemotherapy in ALK-positive non-small-cell lung cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Camidge, D. R. et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol. 13, 1011–1019 (2012).

    Article  CAS  Google Scholar 

  2. Kim, D. W. et al. Results of a global phase II study with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC) [abstract]. J. Clin. Oncol. 30 (Suppl.), a753 (2012).

    Google Scholar 

  3. Shaw, A. T. et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N. Engl. J. Med. 368, 2385–2394 (2013).

    Article  CAS  Google Scholar 

  4. Scagliotti, G. et al. The differential efficacy of pemetrexed according to NSCLC histology: a review of two phase III studies. Oncologist 14, 253–263 (2009).

    Article  CAS  Google Scholar 

  5. Camidge, D. R. et al. Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed. J. Thorac. Oncol. 6, 774–780 (2011).

    Article  Google Scholar 

  6. Mok, T. S. et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 361, 947–957 (2009).

    Article  CAS  Google Scholar 

  7. Davies, K. D. & Doebele, R. C. Molecular pathways: ROS1 fusion proteins in cancer. Clin. Cancer Res. http://dx.doi.org/10.1158/1078-0432.CCR-12-2851.

  8. Ou, S. H. I. et al. Efficacy and safety of crizotinib in patients with advanced ROS1-rearranged non-small cell lung cancer (NSCLC) [abstract]. J. Clin. Oncol. 31 (Suppl.), a8032 (2013).

    Google Scholar 

  9. Awad, M. M. et al. Acquired resistance to crizotinib from a mutation in CD74-ROS1. N. Engl. J. Med. 368, 2395–2401 (2013).

    Article  CAS  Google Scholar 

  10. Camidge, D. R. & Doebele, R. C. Treating ALK-positive lung cancer--early successes and future challenges. Nat. Rev. Clin. Oncol. 9, 268–277 (2012).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Division of Medical Oncology, University of Colorado School of Medicine and University of Colorado Cancer Center, MS 8117, 12801 East 17th Avenue, Aurora, 80045, CO, USA

    Robert C. Doebele

Authors
  1. Robert C. Doebele
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Robert C. Doebele.

Ethics declarations

Competing interests

The author has received research grants from Eli Lilly & Co., ImClone Systems and Pfizer, and advisory board and consulting fees from Boehringer Ingelheim and Pfizer.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Doebele, R. Time to shift the burden of proof for oncogene-positive cancer?. Nat Rev Clin Oncol 10, 492–493 (2013). https://doi.org/10.1038/nrclinonc.2013.135

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrclinonc.2013.135

  • Springer Nature Limited

Search

Navigation